Find Ifosfamide manufacturers, exporters & distributors on PharmaCompass

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

16 API Suppliers, 5 USDMF, 2 CEP/COS, 1 EU WC, 2 NDC API, 12 Listed Suppliers, $ API Reference Price

16 API Suppliers
5 USDMF
2 CEP/COS
1 EU WC
2 NDC API
12 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

51 FDF Dossiers, 16 FDA Orange Book, 13 Europe, 2 Canada, 4 Australia, 3 South Africa, 13 Listed Dossiers

51 FDF Dossiers
16 FDA Orange Book
13 Europe
2 Canada
4 Australia
3 South Africa
13 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 1GM/VIAL, INJECTABLE;INJECTION - 3GM/VIAL

drugProductComposition
INJECTABLE;INJECTION - 1GM/VIAL
INJECTABLE;INJECTION - 3GM/VIAL

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Finar

relatedExcipients
1 Nanjing Well Pharmaceutical
1 Actylis
1 Finar

EXCIPIENTS BY APPLICATIONS

2 Topical, 1 Parenteral, 1 Solubilizers

excipientsByApplications
2 Topical
1 Parenteral
1 Solubilizers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 4 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
4 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

7 Finished Drug Prices

globalSalesInformation
7 Finished Drug Prices

MARKET PLACE

10 APIs, 4 FDF Dossiers

marketPlace
10 APIs
4 FDF Dossiers

REF. STANDARDS & IMPURITIES

6 EDQM , 1 USP , 1 Others

otherSolutions
6 EDQM
1 USP
1 Others

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

4EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Isophosphamide, 3778-73-2, Iphosphamide, Isofosfamide, Ifex, Ifosfamid

Molecular Formula

C₇H₁₅Cl₂N₂O₂P

Molecular Weight

261.08 g/mol

InChI Key

HOMGKSMUEGBAAB-UHFFFAOYSA-N

FDA UNII

UM20QQM95Y

Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.

Ifosfamide is an Alkylating Drug. The mechanism of action of ifosfamide is as an Alkylating Activity.

1 2D Structure

Ifosfamide

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N,3-bis(2-chloroethyl)-2-oxo-1,3,25-oxazaphosphinan-2-amine

2.1.2 InChI

InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)

2.1.3 InChI Key

HOMGKSMUEGBAAB-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1CN(P(=O)(OC1)NCCCl)CCCl

2.2 Other Identifiers

2.2.1 UNII

UM20QQM95Y

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Asta Z 4942

2. Holoxan

3. Iphosphamide

4. Iso Endoxan

5. Iso-endoxan

6. Isofosfamide

7. Isophosphamide

8. Nsc 109,724

9. Nsc 109724

10. Nsc-109,724

11. Nsc-109724

12. Nsc109,724

13. Nsc109724

2.3.2 Depositor-Supplied Synonyms

1. Isophosphamide

2. 3778-73-2

3. Iphosphamide

4. Isofosfamide

5. Ifex

6. Ifosfamid

7. Mitoxana

8. Iphosphamid

9. Isoendoxan

10. Naxamide

11. I-phosphamide

12. Holoxan

13. Cyfos

14. Ifsofamide

15. Holoxan 1000

16. Asta Z 4942

17. Mjf 9325

18. Ifosfamida

19. Ifosfamidum

20. Mjf-9325

21. Isosfamide

22. Nsc-109724

23. Nci-c01638

24. Z4942

25. Z-4942

26. Ifomide

27. Nsc 109724

28. A 4942

29. Z 4942

30. 2h-1,3,2-oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

31. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorine 2-oxide

32. Nsc109724

33. N,3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

34. N-(2-chloroethyl)-n'-(2-chloroethyl)-n',o-propylenephosphoric Acid Diamide

35. Um20qqm95y

36. N,3-bis(2-chloroethyl)tetrahydro-2h-1,3,2-oxazaphosphorin-2-amine 2-oxide

37. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide

38. Chebi:5864

39. Ifosphamide

40. 1,3,2-oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

41. 2h-1,3,2-oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

42. 3-(2-chloroethyl)-2-(2-chloroethylamino)tetrahydro-2h-1,3,2-oxaazaphosphorin 2-oxide

43. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,3,2-oxazaphosphorineoxide

44. N-(2-chloroethyl)-n'-(2-chloroethyl)-n',o-propylene Phosphoric Acid Ester Diamide

45. Ncgc00016639-01

46. Cas-3778-73-2

47. Dsstox_cid_760

48. Ifosfamide Sterile

49. Dsstox_rid_75775

50. Dsstox_gsid_20760

51. Ifosfamidum [inn-latin]

52. Ifosfamida [inn-spanish]

53. (r)-ifosfamide

54. (s)-ifosfamide

55. (r)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide

56. Ccris 352

57. Hsdb 7023

58. Sr-05000002022

59. Einecs 223-237-3

60. Ifex (tn)

61. Unii-um20qqm95y

62. Brn 0611835

63. Ifosfamide (jan/usp/inn)

64. N,3-bis(2-chloroethyl)-2-oxo-1,3,2?^{5}-oxazaphosphinan-2-amine

65. Ifosfamid A

66. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)perhydro-2h-1,3,2-oxazaphosphorineoxide

67. Ifosfamide In Bulk

68. 2,3-(n,n(sup 1)-bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd

69. Isophosphamide,(s)

70. N,n-bis(beta-chloroethyl)-amino-n',o-propylene-phosphoric Acid Ester Diamide

71. N-(2-chloroethyl)-n'-(2-chloroethyl)-n',o-propylenephosphoric Acid Ester Diamide

72. Mfcd00057374

73. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)perhydro-2h-1,3,2-oxazaphosphorine Oxide

74. N-(2-chloraethyl)-n'-(2-chloraethyl)-n',o-propylen-phosphorsaureester-diamid [german]

75. Ifosfamide - Bio-x

76. Ifosfamide [usan:usp:inn:ban:jan]

77. Starbld0001221

78. Ifosfamide, >=98%

79. Ifosfamide [mi]

80. Isocyclophosphamide

81. Ifosfamide [inn]

82. Ifosfamide [jan]

83. Prestwick0_000833

84. Prestwick1_000833

85. Prestwick2_000833

86. Prestwick3_000833

87. Ifosfamide [hsdb]

88. Ifosfamide [usan]

89. Intermediate Of Ifosfamide

90. Ifosfamide [vandf]

91. N-(2-chloraethyl)-n'-(2-chloraethyl)-n',o-propylen-phosphorsaureester-diamid

92. Ifosfamide [mart.]

93. Schembl4885

94. Chembl1024

95. Ifosfamide [usp-rs]

96. Ifosfamide [who-dd]

97. Bspbio_000785

98. Isophosphamide [iarc]

99. Mls002154021

100. Ifex (tn) (bristol Meyers)

101. Spbio_002706

102. Bpbio1_000865

103. Gtpl7201

104. Dtxsid7020760

105. Ifosfamide [ep Impurity]

106. Ifosfamide [orange Book]

107. Ifosfamide [ep Monograph]

108. (s)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide

109. Bdbm189358

110. Hms1570h07

111. Hms2090m12

112. Hms2093n07

113. Hms2097h07

114. Hms2232o10

115. Hms3374b08

116. Hms3654b15

117. Hms3714h07

118. Ifosfamide [usp Monograph]

119. Pharmakon1600-01505480

120. {3-(2-chloroethyl)-2-[(2-

121. Bcp06596

122. Wln: T6npotj Am2g Bo B2g

123. Tox21_110539

124. Tox21_201815

125. Tox21_302775

126. Bbl028071

127. N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine

128. N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine

129. Nsc759154

130. S1302

131. Stl058690

132. Akos005711213

133. N,3-bis(2-chloroethyl)tetrahydro-2h-1,3,2-oxazaphosphorin-2-amine-2-oxide

134. Tox21_110539_1

135. Ab02316

136. Ac-2113

137. Ccg-213464

138. Cs-1424

139. Db01181

140. Nsc-759154

141. N-(2-chloroethyl)-n-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine

142. Ifosfamide, Analytical Reference Material

143. Ncgc00179435-01

144. Ncgc00179435-02

145. Ncgc00179435-03

146. Ncgc00179435-06

147. Ncgc00179435-07

148. Ncgc00256413-01

149. Ncgc00259364-01

150. As-10978

151. Bi166243

152. Hy-17419

153. Nci60_000233

154. Smr001233348

155. Sbi-0206804.p001

156. Db-049196

157. Ab00513932

158. Ft-0603650

159. Ft-0670282

160. I0713

161. Sw197177-4

162. C07047

163. D00343

164. Ab00513932-06

165. Ab00513932-07

166. Ab00513932-08

167. Ab00513932_09

168. Ab00513932_10

169. 778i732

170. A823873

171. Q418560

172. Q-101874

173. Sr-05000002022-1

174. Sr-05000002022-3

175. Sr-05000002022-5

176. Brd-a67097164-001-11-2

177. Ifosfamide, British Pharmacopoeia (bp) Reference Standard

178. Ifosfamide, European Pharmacopoeia (ep) Reference Standard

179. Ifosfamide, United States Pharmacopeia (usp) Reference Standard

180. 2,n(sup 1)-bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-

181. 2,n(sup 1)-bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd

182. N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l;{5}-oxazaphosphinan-2-amine

183. {3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,3,} 2-oxazaphosphorine Oxide

184. 1,2-oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

185. 2h-1,2-oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

186. 2h-1,2-oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

187. 3-(2-chloroethyl)-2-(2-chloroethylamino)tetrahydro-2h-1,3,2-oxazaphosphorin-2-one

188. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one

189. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one

190. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,2-oxazaphosphorine Oxide

191. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,2-oxazaphosphorineoxide

192. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2h-1,2-oxazaphosphorine 2-oxide

193. N,3-bis(2-chloroethyl)tetrahydro-2h-1,3,2-oxazaphosphinan-2-amine 2-oxide #

2.4 Create Date

2005-03-25

3 Chemical and Physical Properties

Molecular Formula	C₇H₁₅Cl₂N₂O₂P
Molecular Weight	261.08 g/mol
XLogP3	0.9
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	5
Exact Mass	260.0248201 g/mol
Monoisotopic Mass	260.0248201 g/mol
Topological Polar Surface Area	41.6 Å²
Heavy Atom Count	14
Formal Charge	0
Complexity	218
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 4
Drug Name	Ifex
PubMed Health	Ifosfamide (Injection)
Drug Classes	Antineoplastic Agent
Drug Label	IFEX (ifosfamide for injection, USP) single-dose vials for constitution and administration by intravenous infusion each contain 1 gram or 3 grams of sterile ifosfamide. Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustard...
Active Ingredient	Ifosfamide
Dosage Form	Injectable
Route	Injection
Strength	1gm/vial; 3gm/vial
Market Status	Prescription
Company	Baxter Hlthcare

2 of 4
Drug Name	Ifosfamide
PubMed Health	Ifosfamide (Injection)
Drug Classes	Antineoplastic Agent
Drug Label	Ifosfamide injection sterile, single-dose vials for administration by intravenous infusion each contains 1 gram or 3 grams of ifosfamide, USP. The 1-gram vial also contains 69.0 mg monobasic sodium phosphate monohydrate, USP, 21.3 mg dibasic sodium p...
Active Ingredient	Ifosfamide
Dosage Form	Injectable
Route	Injection
Strength	1gm/20ml (50mg/ml); 3gm/60ml(50mg/ml); 1gm/vial; 3gm/vial; 1gm/20ml(50mg/ml); 3gm/60ml (50mg/ml)
Market Status	Prescription
Company	Teva Pharms Usa; Fresenius Kabi Usa; Onco Therapies; Eurohlth Intl

3 of 4
Drug Name	Ifex
PubMed Health	Ifosfamide (Injection)
Drug Classes	Antineoplastic Agent
Drug Label	IFEX (ifosfamide for injection, USP) single-dose vials for constitution and administration by intravenous infusion each contain 1 gram or 3 grams of sterile ifosfamide. Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustard...
Active Ingredient	Ifosfamide
Dosage Form	Injectable
Route	Injection
Strength	1gm/vial; 3gm/vial
Market Status	Prescription
Company	Baxter Hlthcare

4 of 4
Drug Name	Ifosfamide
PubMed Health	Ifosfamide (Injection)
Drug Classes	Antineoplastic Agent
Drug Label	Ifosfamide injection sterile, single-dose vials for administration by intravenous infusion each contains 1 gram or 3 grams of ifosfamide, USP. The 1-gram vial also contains 69.0 mg monobasic sodium phosphate monohydrate, USP, 21.3 mg dibasic sodium p...
Active Ingredient	Ifosfamide
Dosage Form	Injectable
Route	Injection
Strength	1gm/20ml (50mg/ml); 3gm/60ml(50mg/ml); 1gm/vial; 3gm/vial; 1gm/20ml(50mg/ml); 3gm/60ml (50mg/ml)
Market Status	Prescription
Company	Teva Pharms Usa; Fresenius Kabi Usa; Onco Therapies; Eurohlth Intl

4.2 Therapeutic Uses

Ifosfamide currently is approved for use in combination with other drugs for germ cell testicular cancer & is widely used to treat pediatric & adult sarcomas. Clinical trials also have shown ifosfamide to be active against carcinomas of the cervix & lung & against lymphomas. It is a common component of high-dose chemotherapy regimens with bone marrow or stem cell rescue; in these regimens, in total doses of 12-14 g/sq m, it may cause severe neurological toxicity, including coma & death. This toxicity is thought to result form a metabolite, chloracetaldehyde. In addition to hemorrhagic cystitis, ifosfamide causes nausea, vomiting, anorexia, leukopenia, nephrotoxicity, & CNS disturbances (especially somnolence & confusion).

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1396

Ifosfamide is indicated, in combination with other antineoplastic agents and a prophylactic agent against hemorrhagic cystitis (such as mesna), for treatment of germ cell testicular tumors. /Included in US product labeling/

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1677

Ifosfamide is indicated as reasonable medical therapy for treatment of head and neck carcinoma. (Evidence rating: IIID) /NOT included in US product labeling/

Ifosfamide is used for treatment of soft-tissue sarcomas, Ewing's sarcoma, and Hodgkin's and non-Hodgkin's lymphomas. /NOT included in US product labeling/

For more Therapeutic Uses (Complete) data for IFOSFAMIDE (9 total), please visit the HSDB record page.

4.3 Drug Warning

It is a common component of high-dose chemotherapy regimens with bone marrow or stem cell rescue; in these regimens, in total doses of 12-14 g/sq m, it may cause severe neurological toxicity, including coma & death. This toxicity is thought to result form a metabolite, chloracetaldehyde. In addition to hemorrhagic cystitis, ifosfamide causes nausea, vomiting, anorexia, leukopenia, nephrotoxicity, & CNS disturbances (especially somnolence & confusion).

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1396

Ifosfamide is distributed into breast milk. Breast feeding is not recommended during chemotherapy because of the risks to the infant (adverse effects, mutagenicity, carcinogenicity).

The bone marrow depressant effects of ifosfamide may result in an increased incidence of microbial infection, delayed healing, and gingival bleeding. Dental work, whenever possible, should be completed prior to initiation of therapy or deferred until blood counts have returned to normal. Patients should be instructed in proper oral hygiene during treatment, including caution in use of regular toothbrushes, dental floss, and toothpicks.

Many side effects of antineoplastic therapy are unavoidable and represent the medication's pharmacologic action. Some of these (for example, leukopenia and thrombocytopenia) are actually used as parameters to aid in individual dosage titration.

For more Drug Warnings (Complete) data for IFOSFAMIDE (20 total), please visit the HSDB record page.

4.4 Drug Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Ifosfamide requires activation by microsomal liver enzymes to active metabolites in order to exert its cytotoxic effects. Activation occurs by hydroxylation at the ring carbon atom 4 to form the unstable intermediate 4-hydroxyifosfamide. This metabolite than rapidly degrades to the stable urinary metabolite 4-ketoifosfamide. The stable urinary metabolite, 4-carboxyifosfamide, is formed upon opening of the ring. These urinary metabolites have not been found to be cytotoxic. N, N-bis (2-chloroethyl)-phosphoric acid diamide (ifosphoramide) and acrolein are also found. The major urinary metabolites, dechloroethyl ifosfamide and dechloroethyl cyclophosphamide, are formed upon enzymatic oxidation of the chloroethyl side chains and subsequent dealkylation. It is the alkylated metabolites of ifosfamide that have been shown to interact with DNA. Ifosfamide is cycle-phase nonspecific.

5.2 MeSH Pharmacological Classification

Antineoplastic Agents, Alkylating

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

IFOSFAMIDE

5.3.2 FDA UNII

UM20QQM95Y

5.3.3 Pharmacological Classes

Alkylating Drug [EPC]; Alkylating Activity [MoA]

5.4 ATC Code

L01AA06

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01A - Alkylating agents

L01AA - Nitrogen mustard analogues

L01AA06 - Ifosfamide

5.5 Absorption, Distribution and Excretion

Route of Elimination

Ifosfamide is extensively metabolized in humans and the metabolic pathways appear to be saturated at high doses. After administration of doses of 5 g/m2 of 14C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in the urine, with about 61% of the dose excreted as parent compound. At doses of 1.62.4 g/m2 only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours.

Volume of Distribution

Ifosfamide volume of distribution (Vd) approximates the total body water volume, suggesting that distribution takes place with minimal tissue binding. Following intravenous administration of 1.5 g/m2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on Day 1 and 0.72 L/kg on Day 5. When given to pediatric patients, the volume of distribution was 211.6 L/m^2.

Clearance

2.40.33 L/h/m^2 [pediatric patients]

Renal excretion & t1/2 are dose & schedule dependent. 60-80% recovered as unchanged drug or metabolite in urine within 72 hr after admin.

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 90-13

The distribution of ifosfamide (IF) and its metabolites 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and ifosforamide mustard (IFM) between plasma and erythrocytes was examined in vitro and in vivo. In vitro distribution was investigated by incubating blood with various concentrations of IF and its metabolites. In vivo distribution of IF, 2DCE, 3DCE and 4OHIF was determined in 7 patients receiving 9 g/m(2)/72 h intravenous continuous IF infusion. In vitro distribution equilibrium between erythrocytes and plasma was obtained quickly after drug addition. Mean (+/-sem) in vitro and in vivo erythrocyte (e)-plasma (p) partition coefficients (P(e/p)) were 0.75+/-0.01 and 0.81+/-0.03, 0.62+/-0.09 and 0.73+/-0.05, 0.76+/-0.10 and 0.93+/-0.05 and 1.38+/-0.04 and 0.98+/-0.09 for IF, 2DCE, 3DCE and 4OHIF, respectively. These ratios were independent of concentration and unaltered with time. The ratios of the area under the erythrocyte and plasma concentration--time curves (AUC(e/p)) were 0.96+/-0.03, 0.87+/-0.07, 0.98+/-0.06 and 1.34+/-0.39, respectively. A time- and concentration-dependent distribution--equilibrium phenomenon was observed with the relative hydrophilic IFM. It is concluded that IF and metabolites rapidly reach distribution equilibrium between erythrocytes and plasma; the process is slower for IFM. Drug distribution to the erythrocyte fraction ranged from about 38% for 2DCE to 58% for 4OHIF, and was stable over a wide range of clinically relevant concentrations. A strong parallelism in the erythrocyte and plasma concentration profiles was observed for all compounds. Thus, pharmacokinetic assessment using only plasma sampling yields direct and accurate insights into the whole blood kinetics of IF and metabolites and may be used for pharmacokinetic-pharmacodynamic studies.

PMID:11745912 Kerbusch T, et al; Biopharm Drug Dispos 22 (3): 99-108 (2001)

... To assess the feasibility of a sparse sampling approach for the determination of the population pharmacokinetics of ifosfamide, 2- and 3-dechloroethyl-ifosfamide and 4-hydroxy-ifosfamide in children treated with single-agent ifosfamide against various malignant tumours. ... Pharmacokinetic assessment followed by model fitting. Patients: The analysis included 32 patients aged between 1 and 18 years receiving a total of 45 courses of ifosfamide 1.2, 2 or 3 g/m2 in 1 or 3 hours on 1, 2 or 3 days. ... A total of 133 blood samples (median of 3 per patient) were collected. Plasma concentrations of ifosfamide and its dechloroethylated metabolites were determined by gas chromatography. Plasma concentrations of 4-hydroxy-ifosfamide were measured by high-performance liquid chromatography. The models were fitted to the data using a nonlinear mixed effects model as implemented in the NONMEM program. A cross-validation was performed. ... Population values (mean +/- standard error) for the initial clearance and volume of distribution of ifosfamide were estimated at 2.36 +/- 0.33 L/h/m2 and 20.6 +/- 1.6 L/m2 with an interindividual variability of 43 and 32%, respectively. The enzyme induction constant was estimated at 0.0493 +/- 0.0104 L/h2/m2. The ratio of the fraction of ifosfamide metabolised to each metabolite to the volume of distribution of that metabolite, and the elimination rate constant, of 2- and 3-dechloroethyl-ifosfamide and 4-hydroxy-ifosfamide were 0.0976 +/- 0.0556, 0.0328 +/- 0.0102 and 0.0230 +/- 0.0083 m2/L and 3.64 +/- 2.04, 0.445 +/- 0.174 and 7.67 +/- 2.87 h(-1), respectively. Interindividual variability of the first parameter was 23, 34 and 53%, respectively. Cross-validation indicated no bias and minor imprecision (12.5 +/- 5.1%) for 4-hydroxy-ifosfamide only. ... We have developed and validated a model to estimate ifosfamide and metabolite concentrations in a paediatric population by using sparse sampling.

PMID:11523727 Kerbusch T, et al; Clin Pharmacokinet 40 (8): 615-625 (2001)

... The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma. ... Twenty patients received 9 or 12 g/m2 ifosfamide administered as a 72-h continuous intravenous infusion. The population pharmacokinetic model was built in a sequential manner, starting with a covariate-free model and progressing to a covariate model with the aid of generalised additive modelling. ... The addition of the covariates weight, body surface area, albumin, serum creatinine, serum urea, alkaline phosphatase and lactate dehydrogenase improved the prediction errors of the model. Typical pretreatment (mean +/- SEM) initial clearance of ifosfamide was 3.03 +/- 0.18 l/h with a volume of distribution of 44.0 +/- 1.8 l. Autoinduction, dependent on ifosfamide levels, was characterised by an induction half-life of 11.5 +/- 1.0 h with 50% maximum induction at 33.0 +/- 3.6 microM ifosfamide. Significant pharmacokinetic-pharmacodynamic relationships (P = 0.019) were observed between the exposure to 2- and 3-dechloroethylifosfamide and orientational disorder, a neurotoxic side-effect. No pharmacokinetic-pharmacodynamic relationships between exposure to 4-hydroxyifosfamide and haematological toxicities could be observed in this population.

PMID:11699611 Kerbusch T, et al; Eur J Clin Pharmacol 57 (6-7): 467-477 (2001)

For more Absorption, Distribution and Excretion (Complete) data for IFOSFAMIDE (6 total), please visit the HSDB record page.

5.6 Metabolism/Metabolites

Primarily hepatic. Ifosfamide is metabolized through two metabolic pathways: ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde. Small quantities (nmol/mL) of ifosfamide mustard and 4-hydroxyifosfamide are detectable in human plasma. Metabolism of ifosfamide is required for the generation of the biologically active species and while metabolism is extensive, it is also quite variable among patients.

Like cyclophosphamide, ifosfamide is activated in the liver by hydroxylation. However, the activation of ifosfamide proceeds more slowly, with greater production of dechlorinated metabolites & chloroacetaldehyde. These differences in metabolism likely account for the higher doses of ifosfamide required for equitoxic effects & the possible difference in antitumor spectrum of the two agents.

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1391

Like cyclophosphamide, isophosphamide requires metabolism by microsomal enzymes to act as a cytotoxic agent. It is rapidly metabolized in many species, including rodents and dogs; the urinary metabolites indicate that a series of reactions take place analogous to those in the metabolism of cyclophosphamide. Acrolein is produced during its oxidative degradation, and one product of the reaction is the ring-opened carboxy derivative. Dogs also rapidly metabolize isophosphamide, and the carboxy derivative and 4-keto isophosphamide have been identified in the urine.

IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V26 243 (1981)

The aim of this study was to develop a population pharmacokinetic model that could describe the pharmacokinetics of ifosfamide. 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide, and calculate their plasma exposure and urinary excretion. A group of 14 patients with small-cell lung cancer received a 1-h intravenous infusion of 2.0 or 3.0 g/m2 ifosfamide over 1 or 2 days in combination with 175 mg/m2 paclitaxel and carboplatin at AUC 6. The concentration-time profiles of ifosfamide were described by an ifosfamide concentration-dependent development of autoinduction of ifosfamide clearance. Metabolite compartments were linked to the ifosfamide compartment enabling description of the concentration-time profiles of 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide. The Bayesian estimates of the pharmacokinetic parameters were used to calculate the systemic exposure to ifosfamide and its metabolites for the four ifosfamide schedules. Fractionation of the dose over 2 days resulted increased metabolite formation, especially of 2-dechloroethylifosfamide, probably due to increased autoinduction. Renal recovery was only minor with 6.6% of the administered dose excreted unchanged and 9.8% as dechloroethylated metabolites. In conclusion, ifosfamide pharmacokinetics were described with an ifosfamide concentration-dependent development of autoinduction and allowed estimation of the population pharmacokinetics of the metabolites of ifosfamide. Fractionation of the dose resulted in increased exposure to 2-dechloroethylifosfamide, probably due to increased autoinduction.

PMID:11488525 Kerbusch T, et al; Cancer Chemother Pharmacol 48 (1): 53-61 (2001)

The anticancer drug ifosfamide is a prodrug requiring activation through 4-hydroxyifosfamide to ifosforamide mustard, to exert cytotoxicity. Deactivation of ifosfamide leads to 2- and 3-dechloroethylifosfamide and the release of potentially neurotoxic chloracetaldehyde. The aim of this study was to quantify and to compare the pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide, 4-hydroxyifosfamide, and ifosforamide mustard in short (1-4 h), medium (24-72 h), and long infusion durations (96-240 h) of ifosfamide. An integrated population pharmacokinetic model was used to describe the autoinducible pharmacokinetics of ifosfamide and its four metabolites in 56 patients. The rate by which autoinduction of the metabolism of ifosfamide developed was found to be significantly dependent on the infusion schedule. The rate was 52% lower with long infusion durations compared with short infusion durations. This difference was, however, comparable with its interindividual variability (22%) and was, therefore, considered to be of minor clinical importance. Autoinduction caused a less than proportional increase in the area under the ifosfamide plasma concentration-time curve (AUC) and more than proportional increase in metabolite exposure with increasing ifosfamide dose. During long infusion durations dose-corrected exposures (AUC/D) were significantly decreased for ifosfamide and increased for 3-dechloroethylifosfamide compared with short infusion durations. No differences in dose-normalized exposure to ifosfamide and metabolites were observed between short and medium infusion durations. This study demonstrates that the duration of ifosfamide infusion influences the exposure to the parent and its metabolite 3-dechloroethylifosfamide. The observed dose and infusion duration dependence should be taken into account when modeling ifosfamide metabolism.

PMID:11408362 Kerbusch T, et al; Drug Metab Dispos 29 (7): 967-975 (2001)

Ifosfamide is a known human metabolite of L-trofosfamide.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

5.7 Biological Half-Life

7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.

The elimination half-life associated with doses of 2.5 g/sq m is 6-8 hr, whereas the elimination half-life associated with doses of 3.5-5 g/sq m is 14-16 hr.

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 91-22

5.8 Mechanism of Action

The exact mechanism of ifosfamide has not been determined, but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra strand cross-links in the DNA results in cell death.

Mechanism of action: metabolites cause alkylation of DNA. /from table/

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 90-12

Ifosfamide, a structural analog of cyclophosphamide, belongs to the oxazaphosphorine class of antitumor alkylating agents which must be activated by the mixed function oxidase system of the liver. The 4-hydroxy oxazaphosphorines are a reactive species capable of interacting with nucleic acids & cellular materials to cause cell damage & death. The 4-hydroxy metabolite spontaneously liberates acrolein in many sites throughout the body & it is this substance that is responsible for oxazaphosphorine urotoxicity. Both ifosfamide & cyclophosphamide produce cystitis characterized by tissue edema & ulceration followed by sloughing of mucosal epithelial cells, necrosis of smooth muscle fibers & arteries, & culminating in focal hemorrhage. The selective urotoxicity of oxazaphosphorine occurs because the bladder contains a very low concn of thiol cmpds (glutathione, cysteine) which, by virtue of their nucleophilic sulfhydryl groups, are able to react & neutralize many reactive chemicals. Because the metabolic activation of ifosfamide proceeds more slowly than that of cyclophosphamide, doses of ifosfamide are 3-4 times higher than those of cyclophosphamide. This explains the higher incidence of urotoxicity associated with ifosfamide.

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 91-21

API SUPPLIERS

01

ChemWerth Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

VMX

Attending

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue

Not Confirmed

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

Polfa Tarchomin

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue

Not Confirmed

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Poland

Virtual Booth

Digital Content

USDMF CEP/COS

JDMF EU-WC NDC KDMF VMF Others AUDIT

04

Aarti Pharmalabs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue

Not Confirmed

Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC

NDC

KDMF VMF ASMF

AUDIT

08

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue

Not Confirmed

09

Biotechnica DWC

Algeria

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue

Not Confirmed

10

Synthland

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Aarti Pharmalabs Ltd

India

PharmaVenue

Not Confirmed

Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Contact Supplier

India

Virtual Booth

Digital Content

IFOSFAMIDE

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 25081

Submission : 2009-07-20

Status : Active

Type : II

02

Baxter Healthcare Corp

U.S.A

PharmaVenue

Not Confirmed

03

Ifotam Co Ltd

Poland

PharmaVenue

Not Confirmed

04

Jiangsu Hengrui Pharmaceuticals Co L...

China

PharmaVenue

Not Confirmed

05

Degussa Huls Ag

Country

PharmaVenue

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629484200,"product":"IFOSFAMIDE BP (PHARMACEUTICAL RAW MATERI ALS)(INV NO.EX\/2853\/21-22 DT.10.08.2021)","address":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),","city":"MUMBAI \/ MAHARASHTRA","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TECHNO DRUGS & INTERMEDIATES","customerCountry":"BANGLADESH","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2769.5","totalValueFC":"13452.3","currency":"USD","unitRateINR":199544.39999999999,"date":"21-Aug-2021","totalValueINR":"997722","totalValueInUsd":"13452.3","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"4009935","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UDYOG KSHETRA,2ND FLOOR,MULUNDGOREGAON LINK ROAD,MULUND (W),, MUMBAI \/ MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658687400,"product":"IFOSFAMIDE PH. EUR. (PHARMACEUTICAL RAW","address":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"VEM PHARMACEUTICALS","customerCountry":"TURKEY","quantity":"16.00","actualQuantity":"16","unit":"KGS","unitRateFc":"1950","totalValueFC":"30773.5","currency":"USD","unitRateINR":152937.5,"date":"25-Jul-2022","totalValueINR":"2447000","totalValueInUsd":"30773.5","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"3039216","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1660933800,"product":"IFOSFAMIDE PH. EUR. (STERILE)(PHARMACEUT","address":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"TO ORDER","customerCountry":"MEXICO","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5000","totalValueFC":"24469.9","currency":"USD","unitRateINR":389400,"date":"20-Aug-2022","totalValueINR":"1947000","totalValueInUsd":"24469.9","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"3613115","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Sterile","supplierPort":"BOMBAY AIR","supplierAddress":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1664821800,"product":"IFOSFAMIDE BP (PHARMACEUTICAL RAW MATERI","address":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO ORDER","customerCountry":"ARGENTINA","quantity":"21.39","actualQuantity":"21.39","unit":"KGS","unitRateFc":"1450","totalValueFC":"29228","currency":"USD","unitRateINR":112435.71762505843,"date":"04-Oct-2022","totalValueINR":"2405000","totalValueInUsd":"29228","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"4618709","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"71, UDYOG KSHETRA, 2nd FLOOR, MULUND GOREGAON LINK ROAD, MULUND (, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1672770600,"product":"IFOSFAMIDE USP-(THIRD COUNTRY EXPORT UND","address":"5\/502, GARDEN ESTATE,,OFF POKHRAN ROAD NO.2, THANE WEST","city":"THANE,MAHARASHTRA","supplier":"AMTEC HEALTHCARE PVT LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"ON TIME SHIPPING SERVICES L.L.C","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.00","actualQuantity":"1000.12","unit":"GMS","unitRateFc":"1.8","totalValueFC":"1846.9","currency":"USD","unitRateINR":150.98188217413912,"date":"04-Jan-2023","totalValueINR":"151000","totalValueInUsd":"1846.9","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"6694819","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"5\/502, GARDEN ESTATE,,OFF POKHRAN ROAD NO.2, THANE WEST, THANE,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1680201000,"product":"IFOSFAMIDE BP (PHARMACEUTICAL RAW MATERI","address":"2ND FLOOR, GODOWN NO. 204 UDYOG KSHETRA, MULUND GOREGAON LINK","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO ORDER","customerCountry":"ARGENTINA","quantity":"30.68","actualQuantity":"30.68","unit":"KGS","unitRateFc":"1360","totalValueFC":"40996.8","currency":"USD","unitRateINR":109908.73533246414,"date":"31-Mar-2023","totalValueINR":"3372000","totalValueInUsd":"40996.8","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"8968119","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"2ND FLOOR, GODOWN NO. 204 UDYOG KSHETRA, MULUND GOREGAON LINK, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684175400,"product":"PHARMACEUTICAL RAW MATERIALS IFOSFAMIDEBP PH EUR IFOSFAMIDE INV NO PEX 0073 23 24 DT 26 04 2023","address":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO","customer":"TO THE ORDER","customerCountry":"URUGUAY","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"1400","totalValueFC":"16139.2","currency":"USD","unitRateINR":110666.66666666667,"date":"16-May-2023","totalValueINR":"1328000","totalValueInUsd":"16139.2","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685039400,"product":"IFOSFAMIDE PHARMACEUTICAL RAW MATERIAL INV NO PEX 0143 23 24 DT 15 05 2023","address":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"HERA BIOPHARMACEUTICAL CO ","customerCountry":"VIETNAM","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"3670","totalValueFC":"3585.1","currency":"USD","unitRateINR":295000,"date":"26-May-2023","totalValueINR":"295000","totalValueInUsd":"3585.1","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686594600,"product":"IFOSFAMIDE USP (PHARMACEUTICAL RAW MATER","address":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"TO ORDER","customerCountry":"UNITED STATES","quantity":"0.48","actualQuantity":"0.48","unit":"KGS","unitRateFc":"8000","totalValueFC":"3662","currency":"USD","unitRateINR":627082.70625000005,"date":"13-Jun-2023","totalValueINR":"300999.699","totalValueInUsd":"3662","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1687199400,"product":"IFOSFAMIDE BP (PHARMACEUTICAL RAW MATERI","address":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO ORDER","customerCountry":"ARGENTINA","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"1360","totalValueFC":"53104.6","currency":"USD","unitRateINR":109124.99325000001,"date":"20-Jun-2023","totalValueINR":"4364999.73","totalValueInUsd":"53104.6","indian_port":"BOMBAY AIR","hs_no":"29419090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"2ND FLOOR, GODOWN No. 204 UDYOG KSHETRA, MULUND GOREGAON LINK, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694629800,"product":"IFOSFAMIDE EP (PHARMACEUTICAL RAW MATERIAL) (INV NO. PEX\/0487\/23-24 DT. 23.08.2023)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"INTROPA SPEDITIONSGESELLSCHAFT","customerCountry":"GERMANY","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"8000","totalValueFC":"795.1","currency":"USD","unitRateINR":660000,"date":"14-Sep-2023","totalValueINR":"66000","totalValueInUsd":"795.1","indian_port":"Bombay Air","hs_no":"29419090","bill_no":"3938280","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703183400,"product":"PHARMACEUTICAL RAW MATERIALS: IFOSFAMIDEBP\/PH.EUR. (IFOSFAMIDE) [INV.NO. PEX\/0838\/23-24 DT. 06.12.2023]","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO ORDER..","customerCountry":"URUGUAY","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"1400","totalValueFC":"14908.1","currency":"USD","unitRateINR":103416.66666666667,"date":"22-Dec-2023","totalValueINR":"1241000","totalValueInUsd":"14908.1","indian_port":"Bombay Air","hs_no":"29419090","bill_no":"6228618","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719599400,"product":"PHARMACEUTICAL RAW MATERIALS: IFOSFAMIDEBP\/PH. EUR.(IFOSFAMIDE)[INV.NO. PEX\/0294\/24-25 DT. 22.06.2024]","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO ORDER..","customerCountry":"URUGUAY","quantity":"14.60","actualQuantity":"14.6","unit":"KGS","unitRateFc":"1400","totalValueFC":"19276.8","currency":"USD","unitRateINR":110220.13698630137,"date":"29-Jun-2024","totalValueINR":"1609214","totalValueInUsd":"19276.8","indian_port":"Bombay Air","hs_no":"29419090","bill_no":"2051500","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721673000,"product":"IFOSFAMIDE (PHARMACEUTICAL RAW MATERIAL)(INV NO.PEX\/0353\/24-25 DT. 11.07.2024)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO ORDER","customerCountry":"ARGENTINA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"1400","totalValueFC":"15857.4","currency":"USD","unitRateINR":110461.25,"date":"23-Jul-2024","totalValueINR":"1325535","totalValueInUsd":"15857.4","indian_port":"Bombay Air","hs_no":"29419090","bill_no":"2628244","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721673000,"product":"IFOSFAMIDE (PHARMACEUTICAL RAW MATERIAL)(INV NO.PEX\/0353\/24-25 DT. 11.07.2024)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO ORDER","customerCountry":"ARGENTINA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"1400","totalValueFC":"16631.1","currency":"USD","unitRateINR":115851,"date":"23-Jul-2024","totalValueINR":"1390212","totalValueInUsd":"16631.1","indian_port":"Bombay Air","hs_no":"29419090","bill_no":"2630057","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Import","activeIngredients":"IFOSFAMIDE","year":"2021","qtr":"Q2","strtotime":1618252200,"product":"IFOSFAMIDE USP, BATCH NO. V6412001043 (RAW MATERIAL FOR CAPTIVE CONSUMPTION)","address":"474, UDYOG VIHAR,PHASE-V,","city":"GURGAON. ,","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"GETWELL PHARMACEUTICAL","customerCountry":"INDIA","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"1000","totalValueFC":"19919.7","currency":"USD","unitRateINR":"74150","date":"13-Apr-2021","totalValueINR":"1483000","totalValueInUsd":"19919.7","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"3553441","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"","customerAddress":"474, UDYOG VIHAR,PHASE-V,"},{"dataSource":"API Import","activeIngredients":"IFOSFAMIDE","year":"2021","qtr":"Q2","strtotime":1622053800,"product":"IFOSFAMIDE USP, BATCH NO. V6412104033, (FOR CAPTIVE CONSUMPTION)","address":"474, UDYOG VIHAR,PHASE-V,","city":"GURGAON. ,","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"GETWELL PHARMACEUTICAL","customerCountry":"INDIA","quantity":"50.00","actualQuantity":"50","unit":"KGS","unitRateFc":"1000","totalValueFC":"50580.7","currency":"USD","unitRateINR":"74100","date":"27-May-2021","totalValueINR":"3705000","totalValueInUsd":"50580.7","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"4102376","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"","customerAddress":"474, UDYOG VIHAR,PHASE-V,"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1627669800,"product":"IFOSFAMIDE, (BATCH NO:V6412104063) (FOR CAPTIVE CONSUMPTION)","address":"474, UDYOG VIHAR,PHASE-V,","city":"GURGAON. ,","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"GETWELL PHARMACEUTICAL","customerCountry":"INDIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"1000","totalValueFC":"25292.9","currency":"USD","unitRateINR":"75400","date":"31-Jul-2021","totalValueINR":"1885000","totalValueInUsd":"25292.9","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"4878659","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"","customerAddress":"474, UDYOG VIHAR,PHASE-V,"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1633026600,"product":"IFOSFAMIDE USP (FOR CAPTIVE CONSUMPTION)","address":"474, UDYOG VIHAR,,PHASE-V,","city":"GURGAON,HARYANA","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"NA","customer":"GETWELL PHARMACEUTICAL","customerCountry":"INDIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"1000","totalValueFC":"24829.1","currency":"USD","unitRateINR":"74400","date":"01-Oct-2021","totalValueINR":"1860000","totalValueInUsd":"24829.1","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"5671807","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"474, UDYOG VIHAR,,PHASE-V,"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637260200,"product":"IFOSFAMIDE","address":"PLOT NO 2 ALEAP INDUSTRIAL ESTATE, NEAR PARAGATI NAGAR GAJULARAMARAM","city":"HYDERABAD TELANGANA,TELANGANA","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"NA","customer":"CELON LABS","customerCountry":"INDIA","quantity":"14.91","actualQuantity":"14.91","unit":"KGS","unitRateFc":"1050","totalValueFC":"18019","currency":"USD","unitRateINR":"90000","date":"19-Nov-2021","totalValueINR":"1341900","totalValueInUsd":"18019","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"6328050","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO 2 ALEAP INDUSTRIAL ESTATE, NEAR PARAGATI NAGAR GAJULARAMARAM"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648233000,"product":"IFOSFAMIDE USP,BATCH NO:6412111103 (FOR CAPTIVE CONSUMPTION)","address":"474, UDYOG VIHAR,,PHASE-V,","city":"GURGAON,HARYANA","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"NA","customer":"GETWELL PHARMACEUTICAL","customerCountry":"INDIA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"1050","totalValueFC":"31781.2","currency":"USD","unitRateINR":"80745","date":"26-Mar-2022","totalValueINR":"2422350","totalValueInUsd":"31781.2","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"8021924","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"474, UDYOG VIHAR,,PHASE-V,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668191400,"product":"IFOSFAMIDE USP, BATCH NO. 6412205083, (FOR CAPTIVE CONSUMPTION)","address":"474, UDYOG VIHAR,,PHASE-V,","city":"GURGAON,HARYANA","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"NA","customer":"GETWELL PHARMACEUTICAL","customerCountry":"INDIA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"1050","totalValueFC":"32344.2","currency":"USD","unitRateINR":"87990","date":"12-Nov-2022","totalValueINR":"2639700","totalValueInUsd":"32344.2","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"3281322","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"474, UDYOG VIHAR,,PHASE-V,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703010600,"product":"IFOSFAMIDE USP,BATCH NO:6412307033,(RAW MATERIAL FOR CAPTIVECONSUMPTION)","address":"474, UDYOG VIHAR,","city":"GURGAON. ,","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"GETWELL PHARMACEUTICAL","customerCountry":"INDIA","quantity":"24.00","actualQuantity":"24","unit":"KGS","unitRateFc":"1070","totalValueFC":"26006","currency":"USD","unitRateINR":"90201","date":"20-Dec-2023","totalValueINR":"2164824","totalValueInUsd":"26006","indian_port":"Delhi Air","hs_no":"29339990","bill_no":"9322634","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"AND EXPORT LIMITEDRM 706, NO. 363 DONGFENG ZHONG ROADGUANGZHOU, CHINA","customerAddress":"474, UDYOG VIHAR,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715884200,"product":"IFOSFAMIDE USP, BATCH NO. 6412310053, 6412403013, (RAW MATERIAL FOR CAPTIVE CONSUMPTION)","address":"128 DEFENCE ENCLAVE, PREET VIHAR,","city":"DELHI,DELHI","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"GETWELL PHARMA INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"1100","totalValueFC":"22262.8","currency":"USD","unitRateINR":"92785","date":"17-May-2024","totalValueINR":"1855700","totalValueInUsd":"22262.8","indian_port":"Delhi Air","hs_no":"29339990","bill_no":"3538424","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"AND EXPORT LIMITEDRM 706, NO. 363 DONGFENG ZHONG ROADGUANGZHOU, CHINA","customerAddress":"128 DEFENCE ENCLAVE, PREET VIHAR,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722882600,"product":"IFOSFAMIDE USP, BATCH NO. 6412404013, 6412404023 (FOR CAPTIVE CONSUMPTION)","address":"128 DEFENCE ENCLAVE, PREET VIHAR,","city":"DELHI,DELHI","supplier":"GUANGZHOU CHEERLAND IMPORT","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"GETWELL PHARMA INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"1500","totalValueFC":"37822.5","currency":"USD","unitRateINR":"126900","date":"06-Aug-2024","totalValueINR":"3172500","totalValueInUsd":"37822.5","indian_port":"Delhi Air","hs_no":"29339990","bill_no":"4910528","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"AND EXPORT LIMITEDRM 706, NO. 363 DONGFENG ZHONG ROADGUANGZHOU, CHINA","customerAddress":"128 DEFENCE ENCLAVE, PREET VIHAR,"}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

08

HIKMA

United Kingdom

Duphat

Not Confirmed

09

MEITHEAL

U.S.A

Duphat

Not Confirmed

10

RISING

U.S.A

Duphat

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

01

Baxter Medical AB

Germany

Duphat

Not Confirmed

Not Confirmed

10

Orifarm AB

Denmark

Duphat

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

01

BAXTER CORPORATION

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

02

BAXTER CORPORATION

U.S.A

Pharma, Lab & Chemical Expo

Country

Pharma, Lab & Chemical Expo

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

01

Sanofi Aventis South Africa (Pty) Ltd

France

Duphat

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

France

Virtual Booth

Digital Content

Regulatory Info : Generic

Registration Country : South Africa

Ifosfamide

Brand Name : Holoxan 500 mg Injection

Dosage Form : INJ

Dosage Strength : 500mg/13 ml

Packaging : 13X1mg/13 ml

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Portfolio PDF

Product Web Link

02

Sanofi Aventis South Africa (Pty) Ltd

France

Duphat

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

France

Virtual Booth

Digital Content

Regulatory Info : Generic

Registration Country : South Africa

Ifosfamide

Brand Name : Holoxan 1 g Injection

Dosage Form : INJ

Dosage Strength : 1000mg

Packaging : 25X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Portfolio PDF

Product Web Link

03

Sanofi Aventis South Africa (Pty) Ltd

France

Duphat

Not Confirmed

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

France

Virtual Booth

Digital Content

Regulatory Info : Generic

Registration Country : South Africa

Ifosfamide

Brand Name : Holoxan 2 g Injection

Dosage Form : INJ

Dosage Strength : 2000mg/50ml

Packaging : 50X1mg/50ml

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Portfolio PDF

Product Web Link

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - INJECTABLE;INJECTION - 1GM/VIAL

USFDA APPLICATION NUMBER - 19763

DOSAGE - INJECTABLE;INJECTION - 3GM/VIAL

USFDA APPLICATION NUMBER - 19763

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Topical

Parenteral

Solubilizers

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

EDQM

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USP

Others

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ifosfamide Manufacturers

A Ifosfamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ifosfamide, including repackagers and relabelers. The FDA regulates Ifosfamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ifosfamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ifosfamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Ifosfamide Suppliers

A Ifosfamide supplier is an individual or a company that provides Ifosfamide active pharmaceutical ingredient (API) or Ifosfamide finished formulations upon request. The Ifosfamide suppliers may include Ifosfamide API manufacturers, exporters, distributors and traders.

click here to find a list of Ifosfamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Ifosfamide USDMF

A Ifosfamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Ifosfamide active pharmaceutical ingredient (API) in detail. Different forms of Ifosfamide DMFs exist exist since differing nations have different regulations, such as Ifosfamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Ifosfamide DMF submitted to regulatory agencies in the US is known as a USDMF. Ifosfamide USDMF includes data on Ifosfamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ifosfamide USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Ifosfamide suppliers with USDMF on PharmaCompass.

Ifosfamide CEP

A Ifosfamide CEP of the European Pharmacopoeia monograph is often referred to as a Ifosfamide Certificate of Suitability (COS). The purpose of a Ifosfamide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ifosfamide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ifosfamide to their clients by showing that a Ifosfamide CEP has been issued for it. The manufacturer submits a Ifosfamide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ifosfamide CEP holder for the record. Additionally, the data presented in the Ifosfamide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ifosfamide DMF.

A Ifosfamide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ifosfamide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Ifosfamide suppliers with CEP (COS) on PharmaCompass.

Ifosfamide WC

A Ifosfamide written confirmation (Ifosfamide WC) is an official document issued by a regulatory agency to a Ifosfamide manufacturer, verifying that the manufacturing facility of a Ifosfamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ifosfamide APIs or Ifosfamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Ifosfamide WC (written confirmation) as part of the regulatory process.

click here to find a list of Ifosfamide suppliers with Written Confirmation (WC) on PharmaCompass.

Ifosfamide NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ifosfamide as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Ifosfamide API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Ifosfamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Ifosfamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ifosfamide NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Ifosfamide suppliers with NDC on PharmaCompass.

Ifosfamide GMP

Ifosfamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ifosfamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ifosfamide GMP manufacturer or Ifosfamide GMP API supplier for your needs.

Ifosfamide CoA

A Ifosfamide CoA (Certificate of Analysis) is a formal document that attests to Ifosfamide's compliance with Ifosfamide specifications and serves as a tool for batch-level quality control.

Ifosfamide CoA mostly includes findings from lab analyses of a specific batch. For each Ifosfamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ifosfamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Ifosfamide EP), Ifosfamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ifosfamide USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Market Place

Home

Post Enquiry

Market Place

Find Ifosfamide manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

16 API Suppliers

5 USDMF

2 CEP/COS

1 EU WC

2 NDC API

12 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

8 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

51 FDF Dossiers

16 FDA Orange Book

13 Europe

2 Canada

4 Australia

3 South Africa

13 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 1GM/VIAL

INJECTABLE;INJECTION - 3GM/VIAL

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

2 Topical

1 Parenteral

1 Solubilizers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

4 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

7 Finished Drug Prices

MARKET PLACE

10 APIs

4 FDF Dossiers

REF. STANDARDS & IMPURITIES

6 EDQM

1 USP

1 Others

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 1,636

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

4EXCIPIENTS BY APPLICATIONS

01

02

03

04

05

06

07

08

09

10

01

02

02

03

03

04

04

05

Degussa Huls Ag

05

Degussa Huls Ag